Across TCGA pan-cancer cohorts, LYPD6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LYPD6 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher LYPD6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LYPD6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, LGG, and UCEC are the cancer types where LYPD6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.138	0.871	<.001	18	view →
LGG	DFS	Median	All	0.083	0.833	<.001	12	view →
UCEC	OS	Median	II,III,IV	1.000	0.463	.026	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: LYPD6 tumor-vs-normal RNA expression · all LYPD6 data types